Pharma BD Deal Intelligence
A ~$521M bet on an FDA-rejected drug turned into a $650M+/year rare-disease blockbuster before generics caught up a decade later
Full analysis, sources & comparables →Neutral deal coverage relying on company statements: Jerini chairman 'confident that Shire's commercial expertise will ensure its successful market…
FIRAZYR peak annual global sales expected to be around $350-400 million... Expected to be accretive for Non GAAP earnings by the second half of 2010; highly…
Shire's $521M takeover offer for Berlin-based Jerini secures Firazyr, a first-in-class bradykinin B2 antagonist for HAE, days after EU approval and adds a…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
EUR 328M; Firazyr (icatibant) hereditary angioedema; Berlin-based
A ~$521M bet on an FDA-rejected drug turned into a $650M+/year rare-disease blockbuster before generics caught up a decade later
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire plc / Jerini AG (this deal) | 2008 | $521M | 85 |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| Shire plc / Baxalta Inc. | 2016 | $32.0B | 77 |
| Shire plc / ViroPharma Incorporated | 2013 | $4.2B | 58 |
| Shire plc / Movetis NV | 2010 | $565M | 37 |
← Browse all deals · How we score deals
More: 2008 deals · Shire plc deals